Trial Profile
A retrospective study evaluating association between cytomegalovirus (CMV) breakthrough in high risk solid organ transplant recipient and valganciclovir dose modification
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Oct 2017
Price :
$35
*
At a glance
- Drugs Valganciclovir (Primary)
- Indications Cytomegalovirus infections
- Focus Therapeutic Use
- 27 Oct 2017 New trial record
- 08 Oct 2017 Results presented at the IDWeek 2017